← Back to Screener
Neurocrine Biosciences Inc (NBIX)
Price$128.41
Favorite Metrics
Price vs S&P 500 (26W)-9.48%
Price vs S&P 500 (4W)-5.26%
Market Capitalization$12.84B
P/E Ratio (Annual)26.83x
All Metrics
P/CF (Annual)16.40x
Book Value / Share (Quarterly)$32.50
P/TBV (Annual)5.41x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)24.32%
Cash Flow / Share (Quarterly)$7.48
Price vs S&P 500 (YTD)-9.97%
Gross Margin (TTM)98.18%
Net Profit Margin (TTM)16.73%
EPS (TTM)$4.66
10-Day Avg Trading Volume1.18M
EPS Excl Extra (TTM)$4.66
Revenue Growth (5Y)22.29%
EPS (Annual)$4.67
ROI (Annual)14.71%
Gross Margin (Annual)98.18%
Net Profit Margin (5Y Avg)12.55%
Cash / Share (Quarterly)$14.79
P/E Basic Excl Extra (TTM)26.83x
Revenue Growth QoQ (YoY)28.33%
EPS Growth (5Y)2.31%
P/E Normalized (Annual)26.83x
ROA (Last FY)10.33%
Revenue Growth TTM (YoY)21.45%
EBITD / Share (TTM)$6.29
ROE (5Y Avg)10.93%
Operating Margin (TTM)21.64%
Cash Flow / Share (Annual)$7.48
P/B Ratio3.95x
P/B Ratio (Quarterly)4.35x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)4.24x
Net Interest Coverage (TTM)6.75x
ROA (TTM)11.62%
EPS Growth QoQ (YoY)47.36%
EV / EBITDA (TTM)18.80x
EPS Incl Extra (Annual)$4.67
Current Ratio (Annual)3.39x
Quick Ratio (Quarterly)3.07x
3-Month Avg Trading Volume1.11M
52-Week Price Return38.52%
EV / Free Cash Flow (Annual)16.20x
P/E Incl Extra (TTM)26.83x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$29.77
P/S Ratio (Annual)4.49x
Asset Turnover (Annual)0.62x
52-Week High$160.18
Operating Margin (5Y Avg)16.04%
EPS Excl Extra (Annual)$4.67
CapEx CAGR (5Y)25.55%
Tangible BV CAGR (5Y)73.41%
26-Week Price Return-5.49%
Quick Ratio (Annual)3.07x
13-Week Price Return-0.92%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.39x
Enterprise Value$12,126.498
Revenue / Share Growth (5Y)21.15%
Asset Turnover (TTM)0.69x
Book Value / Share Growth (5Y)21.96%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.82x
Pretax Margin (Annual)24.66%
Cash / Share (Annual)$14.79
3-Month Return Std Dev30.94%
Gross Margin (5Y Avg)98.36%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)33.31%
EBITDA Interim CAGR (5Y)31.34%
ROE (Last FY)14.71%
Net Interest Coverage (Annual)3.03x
EPS Basic Excl Extra (Annual)$4.67
P/FCF (TTM)17.15x
Receivables Turnover (TTM)4.91x
EV / Free Cash Flow (TTM)16.20x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$4.66
Receivables Turnover (Annual)4.91x
ROI (TTM)16.67%
P/S Ratio (TTM)4.49x
Pretax Margin (5Y Avg)17.24%
Revenue / Share (Annual)$27.91
Tangible BV / Share (Annual)$25.69
Forward P/E20.89x
Free OCF CAGR (5Y)28.04%
Price vs S&P 500 (52W)8.69%
P/E Ratio (TTM)26.83x
EPS Growth TTM (YoY)41.66%
Year-to-Date Return-7.33%
5-Day Price Return-0.15%
EPS Normalized (Annual)$4.67
ROA (5Y Avg)7.61%
Net Profit Margin (Annual)16.73%
Month-to-Date Return-0.23%
Cash Flow / Share (TTM)$2.11
EBITD / Share (Annual)$6.29
EPS Growth (3Y)44.05%
Operating Margin (Annual)21.64%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)16.40x
ROI (5Y Avg)10.35%
P/E Excl Extra (TTM)26.83x
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$4.66
P/TBV (Quarterly)4.69x
P/B Ratio (Annual)4.35x
Inventory Turnover (TTM)0.82x
Pretax Margin (TTM)24.66%
Book Value / Share (Annual)$32.50
Price vs S&P 500 (13W)-1.61%
Net Margin Growth (5Y)-15.55%
Beta0.35x
P/FCF (Annual)17.15x
Revenue / Share (TTM)$27.50
ROE (TTM)16.67%
52-Week Low$92.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.20
4.22
4.22
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
KRYSKrystal Biotech, Inc. Common Stock | 20.17x | 33.95% | 94.08% | — | $264.06 |
About
Neurocrine Biosciences develops and commercializes pharmaceutical treatments for neurological, psychiatric, endocrine, and immunological disorders. Key marketed products address tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids, while a pipeline of candidates spans multiple therapeutic modalities including small molecules, peptides, proteins, antibodies, and gene therapies. The company generates revenue from pharmaceutical product sales.